Roquefort Therapeutics (LON:ROQ) Stock Price Up 78.2% – Still a Buy?

Roquefort Therapeutics plc (LON:ROQ)’s stock price rose 78.2% during trading on Monday . The stock traded as high as GBX 2.70 ($0.03) and last traded at GBX 2.70 ($0.03). Approximately 8,736,267 shares traded hands during trading, an increase of 375% from the average daily volume of 1,839,150 shares. The stock had previously closed at GBX 1.52 ($0.02).

Roquefort Therapeutics Stock Up 65.0 %

The company’s 50 day moving average price is GBX 3.02 and its 200 day moving average price is GBX 3.66. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The firm has a market capitalization of £3.18 million, a price-to-earnings ratio of -2.06 and a beta of 0.05.

Insider Transactions at Roquefort Therapeutics

In other Roquefort Therapeutics news, insider Stephen Paul West bought 400,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The stock was bought at an average cost of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,511.89). Insiders own 60.40% of the company’s stock.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.